2005 Michigan Growth Capital Symposium Announces First Set Of Presenting Life Sciences Companies
ANN ARBOR, Mich., June 2 /PRNewswire/ -- The 2005 Michigan Growth Capital Symposium (MGCS) announced the first set of presenting life sciences companies at this year's 24th annual symposium held June 15 and 16 at the University of Michigan Ross School of Business. The life sciences are one track of 32 presenting companies that include information technology and alternative energy.
"The MGCS is thrilled with the quality level of this year's life sciences companies," said Dr. David J. Brophy, director of the Center for Venture Capital and Private Equity Finance. "It's a testament to the developing strength of the life sciences corridor in Michigan."
The 2005 MGCS conference will showcase 32 companies carefully screened by members of the Midwest venture capital community in information technology, life sciences and alternative energy. These companies represent the highest quality deals in the Midwest. The companies will present on the second day of the conference.
Presenting companies in the field of life sciences include:
Afmedica, Inc., develops products to prevent the excess scarring that can occur inside blood vessels following vascular surgery and adhesions after other surgical procedures.
Careguide, brings the power of ethnography -- the patient's point of view, as scientifically determined -- to healthcare and uncovers false assumptions providers have about the instructions they deliver to patients.
EraGen Biosciences, Inc., is a global molecular diagnostics and drug discovery company that is designing, developing, manufacturing and marketing the next generation of automated genetic testing products for early, accurate diagnosis of every disease.
HandyLab, Inc., is dedicated to the development and manufacture of novel diagnostic products based on its patented microfluidic technology.
Immunetrics, with a mission to become a leading company in inflammatory disease modeling, leverages its technology to develop a pipeline of immunomodulatory drugs.
RedPath, provides specialized diagnostic testing services with its patented platform technology, PathFinderTG(TM).
Velcura Therapeutics(TM), Inc., develops drug therapies that stimulate bone growth for the treatment of osteoporosis, fractures, and other bone disorders.
ZelleRx Corporation, is a biopharmaceutical company developing cancer treatment products based on its proprietary natural killer (NK) cell line, NK- 92.
MGCS is June 15 and 16 at the University of Michigan Ross School of Business, Ann Arbor, Michigan. Further agenda details and online registration for the event are available at http://www.MichiganGCS.com .
About the Michigan Growth Capital Symposium
During the past 24 years, the Michigan Growth Capital Symposium has earned a reputation as the conference "where deals get done" between aspiring entrepreneurs and noted venture capitalists. The conference, hosted by The University of Michigan Ross School of Business's Center for Venture Capital and Private Equity, is one of a series of nationally recognized venture capital, private equity finance seminars and investor events presented by the Center.
Dr. David J. Brophy, director of the Center, teaches and conducts research on private equity markets. For more information and to register, visit the Web site at http://www.MichiganGCS.com .
Michigan Growth Capital SymposiumCONTACT: Jessica Annaloro of Eiler Communications, +1-734-761-3399, orJessica@EilerPR.com
Web site: http://www.MichiganGCS.com/